Methods and products for diagnosing cancer
AssigneeUniversity of Vermont and State Agricultural College
InventorsMarcus Bosenberg, Viswanathan Muthusamy, Sekhar Duraisamy
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and kits for the detection and diagnosis of cancer or precancerous conditions. Methylation of specific genes has been identified as indicative of cancer and methods of the invention, in part, relate to the detection of methylation levels in cells as a determination of cancer or a precancerous condition in the cell.
Claims31
A method for diagnosing cancer or a precancerous condition in a subject, the method comprising:
- determining a level of methylation of one or more genes comprising QPCT, LXN, PCSK1, MFAP2, WFDC1, CDH8 and LRRC2 in a sample from a subject,
- comparing the level of methylation of the one or more genes in the sample to a control level of methylation of the one or more genes,
- wherein a higher level of methylation of the one or more genes in the sample compared to the control level of methylation is diagnostic for cancer or precancerous condition in the subject.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
17-18. (canceled)
(canceled)
23-24. (canceled)
A method for determining onset, progression, or regression, of cancer in a subject, the method comprising:
- determining a level of methylation of one or more genes comprising QPCT, LXN, PCSK1, MFAP2, WFDC1, CDH8 and LRRC2 in a sample obtained from the subject,
- determining the level of methylation of the one or more genes in a second sample obtained from the subject at a later time than the first sample was obtained,
- comparing the level of methylation of the one or more genes in the first sample with the level of methylation of the one or more genes in the second sample,
- wherein a lower level of methylation of the one or more genes in the first sample compared with the level of methylation of the one or more genes in the second sample indicates onset or progression of cancer in the subject, and
- wherein a higher level of methylation of the one or more genes in the first sample compared with the level of methylation of the one or more genes in the second sample indicates regression of cancer in the subject.
26-47. (canceled)
50-65. (canceled)
A method for selecting a course of treatment of a subject having or suspected of having cancer, the method comprising:
- detecting a level of methylation of one or more genes comprising QPCT, LXN, PCSK1, MFAP2, WFDC1, CDH8I and LRRC2 in a sample obtained from a subject,
- comparing the level of methylation of the one or more genes to a control level of methylation of the one or more genes,
- determining the stage and/or type of cancer of the subject based at least in part on the difference in the level of methylation of the one or more genes in the sample compared to the control level of methylation, and
- selecting a course of treatment for the subject appropriate to the stage and/or type of cancer of the subject.
(canceled)
Dependencies are inferred from the claim text.